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Abstract
Background: In the absence of effective drugs, controlling SARS relies on the rapid identification
of cases and appropriate management of the close contacts, or effective vaccines for SARS.
Therefore, developing specific and sensitive laboratory tests for SARS as well as effective vaccines
are necessary for national authorities.
Results: Genes encoding truncated nucleocapsid (N) and spike (S) proteins of SARSCoV were
cloned into the expression vector pQE30 and fusionally expressed in Escherichia coli M15. The
fusion protein was analyzed for reactivity with SARS patients' sera and with anti-sera against the
two human coronaviruses HCoV 229E and HCoV OC43 by ELISA, IFA and immunoblot assays.
Furthermore, to evaluate the antigen-specific humoral antibody and T-cell responses in mice, the
fusion protein was injected into 6-week-old BALB/c mice and a neutralization test as well as a T-
cell analysis was performed. To evaluate the antiviral efficacy of immunization, BALB/c mice were
challenged intranasally with SARSCoV at day 33 post injection and viral loads were determined by
fluorescent quantitative RT-PCR. Serological results showed that the diagnostic sensitivity and
specificity of the truncated S-N fusion protein derived the SARS virus were > 99% (457/460) and
100.00% (650/650), respectively. Furthermore there was no cross-reactivity with other two human
coronaviruses. High titers of antibodies to SRASCoV appeared in the immunized mice and the
neutralization test showed that antibodies to the fusion protein could inhibit SARSCoV. The T cell
proliferation showed that the fusion protein could induce an antigen-specific T-cell response.
Fluorescent quantitative RT-PCR showed that BALB/c mice challenged intranasally with SARSCoV
at day 33 post injection were completely protected from virus replication.
Conclusion: The truncated S-N fusion protein is a suitable immunodiagnostic antigen and vaccine
candidate.
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Background
The epidemic of severe atypical pneumonia, designated
"severe acute respiratory syndrome (SARS)" by the World
Health Organization (WHO) and first observed in Guang-
dong Province of China in November 2002, affected 8422
people and caused 916 deaths in 33 countries and areas
worldwide up to August 7, 2003 [1,2]. A novel coronavi-
rus, SARS-associated coronavirus (SARSCoV), was con-
firmed as the pathogen [3-6]. In the absence of effective
drugs, controlling this disease relies on the rapid identifi-
cation of cases and appropriate management of the close
contacts, or effective vaccines against SARS. Therefore, the
development of both specific and sensitive laboratory
tests for SARS as well as effective vaccines is necessary for
national authorities.
Laboratory tests for SARS based on indirect immunofluo-
rescence assay (IFA) or viral particle lysate enzyme-linked
immunosorbent assay (SARSCoV lysate ELISA) to detect
antibodies against SARSCoV are important methods [7].
However, these methods both require cultivation of
SARSCoV in a biosafety level 3 or 4 laboratory, which is
both dangerous and difficult. Finding a suitable diagnos-
tic test for this virus therefore remains a high priority. A
practical approach towards this goal is to clone and
express the immunodominant genes of SARSCoV.
Several studies have shown that most of the antigenic
epitopes of SARSCoV are located on the nucleocapsid (N)
and spike (S) proteins and that the latter protein has an
important role in viral entry and pathogenesis [8-12].
Other data have shown that the viral N and S proteins of
coronaviruses could induce a specific T cell response [13-
16]. Here, we report the cloning and expression of a trun-
cated S-N fusion protein of SARSCoV and the investiga-
tion of its antigenicity and immunogenicity.
Methods
Viruses and vectors
The pQE30 vector was purchased from Qiagen (Qiagen
GmbH, Hilden, Germany). Escherichia coli M15 was used
as host strain for the vector. The following virus strains
were kindly provided by the Academy of Military Medical
Science and the National Institute for the Control of Phar-
maceutical and Biological Products: The SARSCoV (BJ01);
SARSCoV (GD01); human coronavirus 229E (HCoV229E)
and human coronavirus OC43 (HCoVOC43). All work
with infectious virus was performed in a biosafety level 3
laboratory.
Construction of recombinant expression plasmids
Viral RNA was extracted with TRIzol according to manual
(Invitrogen). All primers were synthesized by the Shang-
hai Sangon Company according to the published DNA
sequences (table 1). Genomic SARSCoV sequences for N
protein as well as for truncated N (321-422aa) and S (264-
680aa) proteins were amplified by RT-PCR in a mixture of
200  μM (each) deoxynucleoside triphosphate, 0.3 μM
(each) primer, 1 U of Taq polymerase (Takara) in 10 mM
Tris-HCl buffer (pH 8.3) supplemented with 2.0 mM
MgCl2 and 50 mM KCl. The PCR reactions were started
with 10 min at 95°C and followed by 35 cycles, with 1
cycle consisting of 45 sec at 94°C, 30 sec at 55°C, and 60
sec at 72°C. A final step of 5 min at 72°C was added to
the last cycle. The fusion gene construct was established
for expression of a truncated S-N fusion protein. The
recombinant plasmids were constructed as described else-
where [17]. All restriction enzymes and ligases were pur-
chased from TaKaRa biotechnology Co., Ltd (Dalian,
China). E. coli M15 was transformed with ligation mix-
tures and the control vector, respectively. The presence of
the target genes in the recombinant plasmids was verified
by gene-specific PCR and sequence analysis.
Table 1: Primers used for target gene by RT-PCR
Primera Primer sequencesb PCR product (bp)
SARS-Nf-4 5'- cgc ggatcctct gat aat gga ccc ca -3' 1266
SARS-Nr-1269 5'- gc ctgcagtta tgc ctg agt tga atc agc aga -3'
229E-Nf-4 5'- cgc ggatccgct aca gtc aaa tgg gct gat -3' 1167
229E-Nr-1170 5'- ccc gtcgactta gtt tac ttc atc aat tat -3'
OC43-Nf-4 5'- cgc ggatcctct ttt act cct ggt aag caa -3' 1344
OC43-Nr-1347 5'- ccc aagctttta tat ttc tga ggt gtc ttc -3'
SARS-tNf-961 5'- cgc ggtaccatt ggc atg gaa gtc aca -3' 309
SARS-tNr-1269 5'- ccc ctgcagtta tgc ctg agt tga atc agc aga -3'
229E-tNf-925 5'- cgc ggatccgtt tcc aaa gag tca ggc aac -3' 246
229E-tNr-1170 5'- ccc gtcgactta gtt tac ttc atc aat tat -3'
OC43-tNf-985 5'- cgc ggatcctta gag ttg gcc aaa gtg -3' 363
OC43-tNr-1347 5'- ccc aagctttta tat ttc tga ggt gtc ttc -3'
SARS-tSf-790 5'- cgc ggatccctc aag tat gat gaa aat ggt aca atc aca -3' 1251
SARS-tSr-2040 5'- gc ggtaccaga cat agt ata agc cac aat aga -3'
a f and r signify forward and reverse primers, respectively.
b underlined sequences indicate restriction sites: BamHI (ggatcc), PstI (ctgcag), SalI (gtcgac), HindIII (aagctt), and KpnI (ggtacc).BMC Microbiology 2008, 8:207 http://www.biomedcentral.com/1471-2180/8/207
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Expression and purification of the recombinant proteins
The materials and methods used for obtaining the recom-
binant proteins were described in detail elsewhere [17].
The transformed bacteria were induced with 2.0 mM IPTG
at 37°C and inclusion bodies containing recombinant
proteins with N-terminal sequences of six consecutive His
residues were serially extracted with 2 M urea and then
dissolved in 8 M urea. It was then subjected to purification
by means of a Ni-NTA Affinity Chromatography Purifica-
tion Kit according to manual (Qiagen GmbH). Recovery
of purified and renatured recombinant proteins from the
denatured state in 8 M urea in buffer A (10 mM Tris-Cl
(pH 7.0), 100 mM NaH2PO4) was achieved by sequential
dialysis against 6 M, 4 M and 2 M urea in buffer A and
finally against buffer A only. In detail, the products were
dialyzed twice against 5 volumes of 6 M urea in buffer A
for 30 min at room temperature. The same procedure was
repeated with 4 M urea and 2 M urea in buffer A. The final
dialysis was against buffer A with two initial changes of
buffer after 30 min each and a final dialysis overnight at
4°C. The purity of the target proteins was determined by
SDS-PAGE [18], see Figure 1.
Human sera
SARS patients' sera: 460 serum samples from SARS conva-
lescents (from 35 to 114 days after the onset of illness)
fulfilling the clinical WHO case definition of SARS, and
whose diagnosis was subsequently confirmed by serocon-
version, were collected in 301 Hospital (Beijing, China)
and 302 Hospital (Beijing, China). All sera were tested
positive by the SARSCoV lysate ELISA IgG Kit (Beijing BGI-
GBI Biotech Corp.), which has been approved by the State
Food and Drug Administration (SFDA) for the detection
of anti-SARSCoV immunoglobulin (Ig) G antibody from
human serum or plasma specimens.
Control sera
Sera from 650 Healthy blood donors were collected by the
Beijing Red Cross blood center from May to October
2003.
Mouse Sera
Polyclonal mouse sera against SARSCoV  (BJ01),  HCoV
229E and HCoV OC43 were prepared in our laboratory
(IFA dilution: 1:5120, 1:5120, 1:10240, respectively) as
were polyclonal mouse sera against purified recombinant
proteins SARSCoV N, HCoV OC43 N, HCoV 229E N (IFA
dilution: 1:5120, 1:2560, 1:5120, respectively). Control
sera were collected from healthy BALB/c mice.
Immunization
Mouse immunization was performed according to estab-
lished protocols [19]. Briefly, sixteen 6-week-old BALB/c
mice were divided into 2 groups and injected subcutane-
ously with 0.1 mL of purified recombinant fusion trun-
cated S-N protein solution (100 μg/mL) and PBS,
respectively, both mixed with an equal volume of paraffin
oil. Immunized mice were boosted after 24 days using the
half dose of antigen by celiac arterial route.
Immunological analyses
Immunoblot analysis
An immunoblot analysis was performed as described in
detail elsewhere [18]. SDS-PAGE analysis was performed
using the Mini-protein 3 Electrophoresis System (BIO-
RAD). The stacking gel and separation gel contained 5%
and 15% acrylamide, respectively. Electrophoresis was
carried out at a constant voltage of 120 V for 180 min. The
proteins were electroblotted onto nitrocellulose mem-
branes. The mouse sera were then tested against each of
the recombinant proteins.
IFA
An indirect immunofluorescence assay (IFA) was per-
formed to detect antibodies to SARSCoV (BJ01), HCoV
229E and HCoV OC43 by using SARSCoV according to
established protocols [20].
ELISA
Microtiter plates (96 wells, Shenzhen Jinchanhua Co. Ltd)
were coated overnight at 4°C with either of the eight
recombinant antigens (four recombinant antigens of
SARSCoV: truncated S protein, N protein, truncated N pro-
tein, and truncated S-N fusion protein; two recombinant
antigens of HCoV229E: truncated N protein, N protein;
SDS-PAGE analysis of the expression and purification target  proteins Figure 1
SDS-PAGE analysis of the expression and purification 
target proteins. Lane 1: purified HCoV229E truncated N 
protein; Lane 2: purified SARSCoV truncated N protein; Lane 
3: purified HCoVOC43 truncated N protein; Lane 4: purified 
HCoV229E N protein; Lane 5: purified SARSCoV N protein; 
Lane 6: purified HCoVOC43 N protein; Lane 7: purified 
SARSCoV truncated S-N fusion protein; Lane 8: purified 
SARSCoV truncated S protein; Lane M: protein molecular 
weight marker.BMC Microbiology 2008, 8:207 http://www.biomedcentral.com/1471-2180/8/207
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two recombinant antigens of HCoVOC43: truncated N
protein, N protein) diluted in 50 mM NaHCO3 buffer (pH
9.6). Each well was rinsed with PBS (phosphate-buffered
saline) containing 0.05% Tween-20 and 3% BSA for
blocking the remaining protein-binding sites. After incu-
bation at 37°C for 1 hour, the plates were washed five
times with the PBS/Tween-20 buffer. Diluted serum sam-
ples (1:10 with PBS) were added to the plates. The plates
were incubated at 37°C for 30 min and washed five times
with the PBS/Tween-20 buffer. After addition of peroxi-
dase-conjugated goat anti-human IgG (diluted 1:2000 in
PBS supplemented with 0.5% of Tween-20 and 1.5% of
BSA) to each well and the plates were incubated at 37°C
for 30 min, then washed five times with the PBS/Tween-
20 buffer before the addition of tetramethyl-benzidine
(TMB)/hydrogen peroxide substrate. Reaction was
stopped by addition of 2 M H2SO4. The OD450/630 value
was measured with a microtiter plate reader in triplicates.
A blank control, a negative control and a positive control
were always included on each plate. The cut-off values for
IgG were 0.16 (three N proteins), 0.12 (truncated S pro-
tein), 0.14 (three truncated N proteins), 0.12 (truncated S-
N protein), respectively, which were calculated as the
mean + 2 SD of the readings given by 1000 blood donor
control sera collected from 2001 to 2002 in Beijing. Sam-
ples were tested again in triplicates when their OD450/630
values were near the cut-off values. For the detection of
mice antibodies, all procedures were the same as for detec-
tion of human antibodies except that peroxidase-conju-
gated goat anti-mice IgG diluted to 1:1000 was used. Mice
sera were diluted to 1:20 with PBS.
Neutralization test
Neutralizing titer (NT) of mouse sera was measured by a
rapid microneutralization assay [21]. In brief, heat-inacti-
vated (55°C for 30 min) mouse immune serum was
diluted tenfold and then serially diluted twofold to
1:2560 in DMEM (Gibco) containing 5% heat-inactivated
fetal calf serum (56°C for 30 min). Approximately 50 μL
of  SARSCoV  (BJ01 strain) (400 TCID50/100  μL) was
mixed with an equal volume of diluted serum and incu-
bated at 35°C for 1 h; then 50 uL of the mixture (contain-
ing 100 TCID50) and 50 μL of DMEM containing 5%
inactivated fetal calf serum were added onto a VeroE6 cell
monolayer in triplicate. The viral cytopathic effect (CPE)
was observed on days 2 and 3. The dilution of serum that
completely prevented CPE in 50% of the wells was calcu-
lated according to the Reed Muench formula [22].
Cross-reactivity among viruses and recombinant proteins
Serological cross-reactivity among different human coro-
naviruses was tested by incubation of SARSCoV-infected
cells with mouse antisera against the two other human
coronaviruses,  HCoV229E and HCoVOC43, and subse-
quent indirect immunofluorescence assay (IFA). To evalu-
ate cross-reactivity among different recombinant proteins
of the three human coronaviruses, the proteins were sub-
jected to immunoblot assays with mouse antisera against
the proteins as well as antisera against the viruses and
were also subjected to ELISA with 460 serum samples
from SARS convalescents as well as mice antisera against
the viruses.
Immune responses to the truncated SARSCoV S-N fusion 
protein
Humoral immune response
Serum samples were collected from the tail veins every 3
days after the initial immunization and the final serum
samples were collected from the orbital plexus for anti-
body level assessment by the SARSCoV lysate ELISA IgG
Kit according to the manufacturer's instruction, except
that peroxidase-conjugated goat anti-human IgG was sub-
stituted by peroxidase-conjugated goat anti-mouse IgG
(Sihuan Sci-Technics Company, Beijing). A value of S/N ≥
2.1 was taken as positive standard.
Spleen lymphocyte immune response
The proliferation of spleen lymphocytes was measured by
colorimetric analysis described previously [23]. Four
BALB/c mice in each group were killed on day 33 after
immunization and their spleens were ground into single-
cell suspensions in RPMI 1640 medium (Gibco) supple-
mented with 10% fetal calf serum. The suspensions were
mixed with 5 volumes of erythrocyte lysis buffer (0.01 M
Tris-HCl pH 7.6; 0.01 M NaCl; 0.005 M MgCl2), incu-
bated for 10 minutes on ice and centrifuged at 400 g for 5
min at 4°C. The pellets were resuspended in RPMI 1640
medium (Gibco) supplemented with 10% fetal calf
serum. They were seeded in triplicates in flat-bottom 96-
well microtiter plates (Costar) with 5 × 105 cells per well
in 100 μL of culture medium with purified and truncated
S-N protein at 10, 3, 1, 0.3 and 0 μg/mL, respectively. After
incubation for 3 days with 5% CO2 at 37°C, 10 μL of a
solution of the tetrazolium salt 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) was added to
each well, and the plates were incubated for 4 h at 37°C.
One hundred microliter of lysis buffer containing 10%
Triton-50% isopropanol-0.01 M hydrochloric acid was
then added to each well, and the plates were incubated
overnight. The optical densities at 570 nm (OD570) and at
630 nm (OD630) were measured.
SARSCoV challenge and determination of virus load
Four BALB/c mice from each group, immunized as well as
controls, were challenged intranasally with 104 TCID50 of
the SARSCoV GD01 strain on day 33 after immunization
to tested the heterologous protection. After two days of
clinical observation the mice were sacrificed and their
lungs were collected for determination of the level of viral
RNA.BMC Microbiology 2008, 8:207 http://www.biomedcentral.com/1471-2180/8/207
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Fifty mg lung tissue was first homogenized in liquid nitro-
gen and then in 1 mL of TRIzol. Tissue homogenates were
clarified by low-speed centrifugation (3000 rpm). RNA
extraction was performed according to manual (Invitro-
gen). Virus loads were determined by fluorescent quanti-
tative RT-PCR and expressed as number of copies per gram
tissue [24].
Results
Serological cross-reactivity among coronaviruses and 
recombinant proteins
The result of immunofluorescence analysis of cross-reac-
tivity between SARSCoV-infected cells and mouse antisera
against each N protein of the three coronaviruses is shown
in Figure 2. The results show that mouse anti-sera to
HCoV229E N protein and HCoVOC43 N protein cross-
react with SARSCoV. Figure 3 shows the result of immuno-
blot analyses for cross-reactions between (i) intact N pro-
tein from the three human coronaviruses plus the
truncated S protein and mouse antisera against each coro-
navirus (panels A, B, and C) and (ii) truncated N protein
from each coronavirus and mouse antisera against each
coronavirus (panels D, E and F). The results showed (a)
cross-reactions between the intact N proteins and the
antisera against the three coronaviruses and (b) no cross-
reaction between the antisera and the truncated proteins.
The recombinant proteins of HCoV229E and HCoVOC43
were also tested with 460 serum samples from SARS con-
valescents by ELISA. The results showed 34 and 21 sera
were tested positive by N proteins of HCoVOC43 and
HCoV229E respectively, while none of the sera were tested
positive by both truncated N proteins of HCoVOC43 and
HCoV229E.
Diagnostic sensitivity and specificity of ELISA with 
truncated S-N fusion protein as antigen
The qualities of truncated S protein, N protein, truncated
N protein and truncated S-N fusion protein as diagnostic
antigens were evaluated by ELISA technique as described
in Materials and Methods. All 460 SARS patients' sera
were tested against all four antigens. Only 3 samples were
tested negative in the truncated S-N fusion protein assay,
whereas 62, 38 and 43 samples were tested negative in the
truncated S protein, N protein and truncated N protein
assays, respectively (Table 2). Compared with SARSCoV
lysate ELISA, the sensitivity of ELISA with truncated S pro-
tein, N protein, truncated N protein and truncated S-N
fusion protein as antigens were 86.5% (398/460), 91.7%
(422/460), 90.7% (417/460) and > 99% (457/460),
respectively. To evaluate the specificity of these assays, the
sera of the 650 healthy people were tested. Only a few
gave a positive reaction with either SARSCoV lysate or N
protein, whereas none reacted against the truncated pro-
teins (Table 2). To further evaluate the specificity of the
truncated S-N fusion protein, the polyclonal mouse sera
against  SARSCoV  (BJ01),  HCoV229E and HCoVOC43
antisera to were tested by ELISA. Only mice antiserum
against SARSCoV(BJ01) tests positive.
Specific humoral and cellular anti- SARSCoV immune 
responses to the truncated S-N fusion protein
Sera antibody tests showed the ability of the fusion pro-
tein to induce the generation of SARS-specific antibodies
in the immunized mice. Nine to twelve days after injec-
tion, the specific Ig G antibody could be detected. To test
whether the mouse sera against the truncated S-N protein
were able to neutralize SARSCoV, a property that is likely
to be crucial in the defense against virus infection, the
SARSCoV BJ01 strain was used in a microneutralization
assay as described in Materials and Methods. The serum
titer of neutralizing antibodies against SARSCoV  was
2.425 ± 0.209 (Lg dilution ± SD)
The lymphocytes proliferation assay showed that the trun-
cated S-N protein could induce T cell proliferation of mice
immunized with the truncated fusion protein (Table 3).
There are significant differences between mice immunized
with the truncated fusion protein and the controls (t test
p = 0.0084 < 0.05).
Protection from SARSCoV challenge and virus replication
No clinical signs of illness were observed in either group
of SARS-challenged mice. The analysis for SARSCoV
genome copies in the lungs of immunized mice and con-
IFA analysis of cross-reaction of the SARSCoV infected cell  using mouse anti-sera to recombinant N proteins of other  two human Coronaviruses Figure 2
IFA analysis of cross-reaction of the SARSCoV 
infected cell using mouse anti-sera to recombinant N 
proteins of other two human Coronaviruses. A: 
Reacted with mouse anti-serum to SARSCoV N protein; B: 
Reacted with mouse anti-serum to HCoV229E N protein; C: 
Reacted with mouse anti-serum to HCoVOC43 N protein; D: 
Reacted with mouse serum from controls injected with PBS;BMC Microbiology 2008, 8:207 http://www.biomedcentral.com/1471-2180/8/207
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trols was performed. The mean of virus genome copy
numbers are 20708 ± 6202 (copies/g ± SD) per 1 gram
lung tissue in the control group, whereas virus loads in
mice immunized with truncated S-N protein were below
the limit of detection.
Discussion
SARS, a newly emerged infectious disease which caused
worldwide outbreak in 2003, has been a crucial public
health problem. Establishing specific and convenient lab-
oratory tests for SARS and finding a vaccine for this virus
are of high priority.
Immunoblot assay analysis of cross-reaction of the coronaviruses recombinant proteins using mouse anti-sera to three differ- ent human Coronaviruses and recombinant proteins Figure 3
Immunoblot assay analysis of cross-reaction of the coronaviruses recombinant proteins using mouse anti-sera 
to three different human Coronaviruses and recombinant proteins. A: Reacted with mouse anti-serum to HCoV229E; 
B: Reacted with mouse anti-serum to SARSCoV; C: Reacted with mouse anti-serum to HCoVOC43; Lane 1: Purified HCoV229E N 
protein; Lane 2: Purified HCoVOC43 N protein; Lane 3: Purified SARSCoV N protein; Lane 4: Purified SARSCoV truncated S pro-
tein; D: Reacted with mouse anti-serum to SARSCoV; E: Reacted with mouse anti-serum to HCoV229E; F: Reacted with mouse 
anti-serum to HCoVOC43; Lane 5: Purified SARSCoV truncated N protein; Lane 6: Purified HCoV229E truncated N protein; Lane 
7: Purified HCoVOC43 truncated N protein.BMC Microbiology 2008, 8:207 http://www.biomedcentral.com/1471-2180/8/207
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Previous data have shown a high degree of sequence sim-
ilarity between the nucleocapsid (N) proteins of coronavi-
ruses and demonstrated serious serological cross-
reactions [25,26]. We aligned the N protein of five human
coronaviruses (SARSCoV,  HCoV229E,  HCoVNL63,
HCoVOC43 and HCoVHKU1) and found several fairly
homologous regions, e.g. SARSCoV 57-210aa, 258-320aa.
In these regions, the N protein of SARSCoV is 35–39%
identical in amino acid sequence to the N protein of HCoV
229E and HCoV NL63 and 47–50% identical in amino
acid sequence to that of HCoVOC43 and HCoVHKU1
(Figure 4). We also found that the C-terminal of the N
protein (SARSCoV  321-422aa) has lower identity in
amino acid sequence among these human coronaviruse
(Figure 4). In addition, our previous research showed that
some unique highly antigenic sites are located in the C-
terminal part of the SARS N protein and in the 270-667aa
of the SARS spike (S) protein [8]. Other research also
showed that the C-terminal part of the SARS N protein
was highly antigenic [27]. In the present study, using the
pQE30 expression vector we cloned the N genes, gene seg-
ments encoding the C-terminal parts of the N proteins
from all three coronaviruses, as well as SARSCoV gene seg-
ments encoding a truncated spike protein (264-680 aa)
and a truncated S-N fusion protein, respectively. All pro-
teins were highly expressed in E. coli M15. To evaluate the
cross-reactivity of these recombinant proteins and viruses,
IFA and immunoblot assays were performed. The results
(Figures 2 and 3) showed that the truncated proteins only
reacted with species-specific antiserum while the N pro-
teins cross-reacted as did the viruses. The further ELISA
results also showed that the intact N proteins of
HCoV229E and HCoVOC43 cross-reacted with SARS
patients' sera (21/460, 34/460 respectively) while the
truncated N proteins did not cross-react with SARS
patients' sera.
Using the purified proteins as antigens in ELISA assays for
antibodies in the sera of SARS patients we found that the
assay using truncated S-N fusion protein has a clearly
higher sensitivity than those using intact N protein or
truncated S and N proteins, and virtually as high as the
assay using whole SARSCoV lysate (Table 2). The results
indicated the N and S protein were complementary in
detecting SARS-specific antibodies. This is consistent with
previous studies [28,29]. Five positive sera to SARSCoV
lysate antigen were all tested positive against SARSCoV N
protein but negative against SARSCoV truncated N-S pro-
tein. These sera were also tested positive against N pro-
teins of HCoV229E and HCoVOC43 (data not shown),
which could be reasonably explained partly by existence
of other HCoV infections in these humans. The truncated
S-N fusion protein was also subjected to ELISA with mice
antisera against SARSCoV  (BJ01),  HCoV229E and
HCoVOC43. Only mice antiserum against
SARSCoV(BJ01) tests positive. These results showed that
the SARSCoV truncated N-S protein had high specificity.
Considering the difficulty of SARSCoV lysate antigen pro-
Table 2: Antibody detection rates for recombinant protein ELISA and SARSCoV lysate ELISA of sera from SARS patients and healthy 
controls.
Coating antigen Sera of SARS patients Sera of healthy blood donors
Positive negative Positive negative
SARSCoV lysate 460 0 5 645
truncated S protein 398 62 0 650
N protein 422 38 8 642
truncated N protein 417 43 0 650
truncated S-N protein 457 3 0 650
Table 3: Effects of recombinant protein on spleen cell proliferation in mice injected with recombinant proteins and a control group of 
mice injected with PBS by MTTa
Group Proliferation (D valueb ± SD) with the following concentration (μg/ml) of recombinant proteins
10 3 1 0.3 0
PBS Control 0.116 ± 0.112 0.074 ± 0.046 0.011 ± 0.002 0.022 ± 0.008 0.043 ± 0.008
truncated S-N 0.603 ± 0.118 0.551 ± 0.019 0.542 ± 0.216 0.476 ± 0.274 0.068 ± 0.021
a Four BALB/c mice of each group were killed. Spleens were harvested and lymphocyte cultures (Three repeats) were stimulated in vitro for 3 days 
with medium or with various concentrations of purified recombinant fusion truncated S-N protein (three repeats). The truncated S-N protein 
could induce T cell proliferation and significant differences were found between the groups of mice immunized with recombinant protein or 
injected with PBS (T test P = 0.0084 < 0.05).
b D Value = D570-D630-blankBMC Microbiology 2008, 8:207 http://www.biomedcentral.com/1471-2180/8/207
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duction and its false positive ratio (~0.77%, Table 2), the
truncated S-N fusion protein is a suitable diagnostic anti-
gen for detection of SARSCoV antibodies.
The S protein of SARSCoV is an important determinant of
tissue tropism, as it mediates virus and cellular membrane
fusion. Analysis of neutralizing epitopes showed that the
receptor-binding region of the S protein plays an impor-
tant role in virus infection [12,30,31]. A DNA vaccine
study of SARSCoV has also shown that the S protein can
induce protective immune responses to SARSCoV [32].
Moreover, some data showed that the N protein of
SARSCoV could induce specific T-cell responses and stud-
ies of animal coronaviruses have suggested that both cel-
lular and humoral immunity contribute to protection
during persistent infection [13,16,33]. Considering that
our fusion protein includes the receptor-binding region of
the S protein and immunodominant T-cell epitopes of the
N protein, we also investigated the role of the truncated S-
N protein in anti-SARSCoV infection. Seven to nine days
after injection of the fusion protein, the mice began to
show seropositive for SARS antibodies. After the first
booster, all mice generated high titer of SARS-specific anti-
bodies and the antibodies could neutralize the SARSCoV
infectivity. In the lymphocytes proliferation assay, the
truncated S-N protein could induce T cell proliferation
(Table 3). Compared to the control group, the mice
immunized with the truncated S-N protein were protected
from SARSCoV challenge, as indicated by a lack of detect-
able viral RNA. Therefore, in addition to being a valuable
diagnostic antigen the truncated S-N fusion protein is a
potential candidate for the development of a SARS subu-
nit vaccine.
Conclusion
The truncated S-N fusion protein has high sensitivity and
specificity and it is a suitable diagnostic antigen for detec-
tion of SARSCoV antibodies. On the other hand, it could
induce the mice generated high titer of SARS-specific neu-
tralizing antibodies and T cell proliferation. The mice
immunized with the truncated S-N protein were protected
from SARSCoV challenge. It is also a potential candidate
for the development of a SARS subunit vaccine.
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